Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and safety of nafamostat mesilate in pediatric continuous renal replacement therapy: a 5-year retrospective study in South Korea

  • Hyunseung Noh (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Heeyeon Cho (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Jinwoon Joung (Graduate School of Medicine, Sungkyunkwan University School of Medicine)
  • Received : 2026.02.11
  • Accepted : 2026.05.24
  • Published : 2026.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study aimed to evaluate the efficacy and safety of a nafamostat mesilate (NM) protocol in pediatric patients undergoing continuous renal replacement therapy (CRRT). Methods: A retrospective review was performed in 107 patients who underwent at least 24 hours of CRRT between January 2018 and December 2022 at Samsung Medical Center. According to the anticoagulation strategy used during CRRT, patients were categorized into three groups: no anticoagulation (Group 1), NM (Group 2), and heparin (Group 3). Results: A total of 107 patients (mean age 7.8±5.5 years) were included. The mean duration of CRRT was 11.7 days, and the overall survival rate was 61.7%. NM and heparin were administered to 38 and 27 patients, respectively, whereas 42 patients received no anticoagulant therapy. Mean filter life did not differ significantly among the groups (no anticoagulation 32.1 hours vs. NM 26.7 hours vs. heparin 33.9 hours; P=0.092). However, among 11 patients in the NM group who initiated NM during ongoing CRRT because of inadequate filter lifespan without anticoagulation, hemofilter lifespan significantly increased from 19.8±7.7 to 27.0±9.4 hours after NM initiation (P=0.030). No known complications associated with NM use were observed. One patient experienced minor bleeding at the peritoneal dialysis catheter site during heparin administration. Survival rates did not differ significantly among the groups. Conclusions: NM appears to be a safe anticoagulation option in pediatric CRRT patients at high bleeding risk. While overall filter life was comparable across groups, NM significantly prolonged hemofilter lifespan in patients switched from no anticoagulation, supporting its potential role as a rescue strategy.

Keywords

References

  1. ZhangW,Bai M,YuY,ChenX,Zhao L,ChenX, et al.Continuous renal replacement therapy without anticoagulation in critically ill patients at high risk of bleeding: a systematic review and meta-analysis.SeminDial 2021;34:196-208.
  2. Lee ST, Cho H. The use of nafamostat mesilate as an anticoagulant during continuous renal replacement therapy for children with a highriskofbleeding.JKoreanSocPediatrNephrol 2014;18:98-105.
  3. Deep A. Anticoagulation strategies in continuous kidney replacementtherapy:doesone size fit all?PediatrNephrol 2022;37:2525-9.
  4. Rewa OG, Villeneuve PM, Lachance P, Eurich DT, Stelfox HT, Gibney RTN, et al. Quality indicators of continuous renal replacementtherapy (CRRT) care in critically ill patients: a systematic review. IntensiveCareMed2017;43:750-63.
  5. Mottes TA, Goldstein SL, Basu RK. Process based quality improvement using a continuous renal replacement therapy dashboard. BMCNephrol 2019;20:17.
  6. Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 2007;11:218.
  7. Baek NN, Jang HR, Huh W, Kim YG, Kim DJ, Oh HY, et al. The role of nafamostat mesylate in continuous renal replacement therapy amongpatients athighriskofbleeding.RenFail 2012;34:279-85.
  8. Liu D, Zhao J, Xia H, Dong S, Yan S, Zhuang Y, et al. Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacementtherapy inpatients athighrisk of bleeding: a retrospective single-center study.Eur JMedRes 2024;29:72.
  9. Yang JW, Han BG, Kim BR, Lee YH, Kim YS, Yu JM, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage.RenFail 2009;31:668-75.
  10. Makino S, Egi M, Kita H, Miyatake Y, Kubota K, Mizobuchi S, et al. Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy. Int J ArtifOrgans 2016;39:16-21.
  11. Hwang SD, Hyun YK, Moon SJ, Lee SC, Yoon SY. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy. Int J ArtifOrgans 2013;36:208-16.
  12. Kim T, Kim DE, Jo EM, Lee Y, Kim DW, Kim HJ, et al. The role of nafamostat mesylate anticoagulation in continuous kidney replacement therapy for critically ill patients with bleeding tendencies: a retrospective study onpatient outcomes andsafety. KidneyResClin Pract 2024;43:469-79.
  13. Zeng X, Cai X, Liao Z, Xiao Y, Wu J, Guan X, et al. Effect of nafamostat mesylate anticoagulation and regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients: a retrospective study of efficacy and safety. Ren Fail 2025;47:2580058.
  14. ChoiJY,KangYJ,JangHM,JungHY,ChoJH,ParkSH, et al.Nafamostat mesilate as an anticoagulant during continuous renal replacement therapy in patients with high bleeding risk: a randomized clinical trial.Medicine (Baltimore) 2015;94:e2392.
  15. Kameda S, Fujii T, Ikeda J, Kageyama A, Takagi T, Miyayama N, et al. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study.BMCNephrol 2023;24:12.
  16. Miyaji MJ, Ide K, Takashima K, Maeno M, Krallman KA, Lazear D, et al. Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy. Pediatr Nephrol 2022;37:2733-42.
  17. He J, Zhang X. Comparison of different anticoagulation methods in continuous renal replacement therapy for pediatric acute liver failure patients: a retrospective observational study. Front Pediatr 2025;13:1667760.
  18. Song C, Li R, Tang S, Tang S, Zhang P, Bai M, et al. Different anticoagulation methods for continuous renal replacement therapy in patientswithhyperlactataemia andahighriskofbleeding.IntJArtif Organs 2025;48:639-52.